Clobetasol propionate

What it is

Clobetasol propionate is a synthetic halogenated corticosteroid applied to the skin, classified as super-high potency (class I), the most powerful group of topical steroids. It is marketed in several topical forms; the label recorded here is the 0.05% cream, and one of the trials below used a 0.05% shampoo. The label is written for corticosteroid-responsive dermatoses generally rather than one named disease, and it caps use at two consecutive weeks and 50 g per week because of the risk of suppressing the adrenal axis. The label also states it should not be used on the face, groin or axillae, or in rosacea or perioral dermatitis, and that use under 12 years of age is not recommended.

What the research says

Topical corticosteroids reduce inflammation, itching and redness in the skin, and in a network meta-analysis of 22,028 patients potent and very potent steroids ranked at the top for plaque psoriasis, while coal tar and retinoids were no better than placebo. The same analysis found no significant advantage of very potent steroids such as clobetasol over ordinary potent steroids, and found investigators rating the response about twice as favourably as patients did. In genital lichen sclerosus, an off-label use, a Cochrane review found clobetasol clearly better than placebo. For alopecia areata, Cochrane found no corticosteroid benefit over placebo. The harms are dose- and site-dependent and well documented: skin atrophy and striae, burning and stinging, suppression of the hypothalamic-pituitary-adrenal axis at doses as low as 2 g a day for a week, published cases of iatrogenic Cushing's syndrome including in infants, and a contested but repeatedly described withdrawal syndrome after prolonged misuse.

Evidence grade: Well established.

How it works

Drug class: Super-high potency (class I) topical corticosteroid

Clobetasol reduces inflammation, itching and blood-vessel widening in skin. The label says the mechanism of topical steroids is unclear and offers only a postulated route: the steroid induces proteins called lipocortins that block an enzyme releasing arachidonic acid, the raw material for prostaglandins and leukotrienes that drive inflammation. (Source 1)

What it is used for

• A network meta-analysis of 48 trunk/limb and 17 scalp psoriasis studies placed potent and very potent corticosteroid strategies at the top of the efficacy ranking, and a randomised maintenance trial of clobetasol shampoo kept 31.1% relapse-free at six months versus 8.1% on vehicle. The same meta-analysis found no significant advantage over ordinary potent steroids. Evidence: established. (Source 2)
• A Cochrane review of 7 small trials in 249 people found clobetasol propionate 0.05% better than placebo for participant-rated symptom improvement (risk ratio 2.85) and investigator-rated improvement, while calling the overall evidence limited and the trials small. Evidence: limited. (Source 3)
• A Cochrane review of 17 trials in 540 people found that none of the interventions tested, topical corticosteroids among them, produced significant hair growth compared with placebo, and that most trials were too small and poorly reported to be conclusive. Evidence: not-supported. (Source 4)

Interactions

• Corticosteroids taken by any other route (tablets, inhalers, nasal sprays, injections) (clinical trial): Clobetasol is absorbed through the skin into the bloodstream, so its effect on the adrenal axis adds to that of any other steroid being taken. A meta-analysis of 74 studies found adrenal insufficiency after corticosteroids by every route studied, with no route, dose or duration that can be assumed safe. (Source 5)
• Topical antifungals and antibacterials for a co-existing skin infection (label): Corticosteroids suppress local immune defence, so if a fungal or bacterial skin infection is present or develops, the label directs that an appropriate antifungal or antibacterial be used and that clobetasol be stopped until the infection is controlled. (Source 6)
• Food, alcohol and dietary supplements (label): We found no food, alcohol or supplement interaction described for topical clobetasol in the FDA label or in the trials and reviews we read. What the label does name as determining how much drug reaches the bloodstream is the surface area treated, occlusion of the treated skin, and how long treatment continues. (Source 7)

Stopping it

• The label frames stopping as the normal endpoint rather than a problem: therapy is to be discontinued once control is achieved, and the diagnosis reassessed if there is no improvement within two weeks. (Source 8)
• Because absorbed clobetasol can suppress the adrenal axis, the label warns of glucocorticosteroid insufficiency after withdrawal and says that although recovery is generally prompt, some patients infrequently need supplemental systemic corticosteroids. (Source 7)
• A systematic review of 34 studies describes topical corticosteroid withdrawal as a distinct adverse effect of misuse, with burning, stinging and erythema after stopping, most often following prolonged inappropriate use of potent steroids on the face or genitals. (Source 9)
• In the published cases of iatrogenic Cushing's syndrome from clobetasol, adrenal recovery after stopping took months rather than days, averaging about 3.5 months in children and 3.8 months in adults. (Source 10)

What goes wrong

In a randomised 28-day study in moderate-to-severe psoriasis, 30.0% of patients using the standard clobetasol propionate 0.05% cream had an abnormal ACTH stimulation test, indicating measurable suppression of the adrenal stress response. (Source 11)

• Randomized trial, Low certainty.
• Size: 88 patients randomised across three arms (n = 30 on 0.05% cream)
• Who: Indian adults with moderate-to-severe psoriasis.
• How long: 28 days of twice-daily application.
• Result: Abnormal ACTH stimulation test (cortisol <= 18 ug/dl) at day 28 in 30.0% on 0.05% cream, 20.7% on one 0.025% formulation and 17.2% on the other (p = 0.320, not statistically significant between formulations)
• Funding: Industry-funded study of new lower-strength formulations (investigator-blinded phase 2a)

At day 28, the proportion of patients with an abnormal ACTH stimulation test (cortisol levels ≤ 18 µg/dl) was numerically lower in 0.025% formulations: 5 (20.7%) and 13 (17.2%) compared with 0.05% cream (30.0%)

A review of published cases identified at least 43 reports of iatrogenic Cushing's syndrome caused by very potent topical steroid use, specifically clobetasol, over 35 years, including infants treated for diaper dermatitis. (Source 10)

• Case series, Very low certainty.
• Size: At least 43 published cases (22 children, 21 adults) plus one new case report.
• Who: Children, mostly infants with diaper dermatitis, and adults, most often treated for psoriasis.
• How long: Prolonged use; HPA axis recovery took a mean of about 3.5 to 3.8 months.
• Result: 43 or more cases over 35 years; two infants who began application very early died from severe disseminated CMV infection; recovery of HPA axis suppression 3.49 +/- 2.92 months in children and 3.84 +/- 2.51 months in adults.
• Funding: Not stated in the recorded abstract.

At least 43 cases with iatrogenic Cushing syndrome from very potent topical steroid usage (Clobetasol) in children and adult have been published over the last 35 years particularly in developing countries.

A systematic review of topical corticosteroid withdrawal pooled 34 studies describing a burning and reddening syndrome after potent topical steroids are stopped, reported most often on the face and genital area and most often in women, after long-term inappropriate use. (Source 12)

• Systematic review, Very low certainty.
• Size: 34 studies met inclusion criteria out of 294 search results.
• Who: Patients with atopic dermatitis and other dermatoses who had used potent topical corticosteroids long term.
• How long: Not stated; the pattern described follows prolonged use.
• Result: Of the cases written up across the 34 included studies, the review reports the face and genital area in 99.3%, women in 81.0%, burning and stinging as the commonest symptom in 65.5% and erythema as the commonest sign in 92.3% - percentages the paper publishes without stating a denominator for any of them.
• Funding: Prompted by patient enquiries to the National Eczema Association; funding not stated in the recorded abstract.

Limit of this finding: Every percentage in this passage is published without a denominator anywhere in the paper, and all of them are pooled across 34 studies of very different kinds. The 99.3% cannot be read as '99 of every 100 affected people get it on the face or genitals'; it describes where the cases that happened to be written up were located, which is shaped by who gets reported. The review's own Limitations section calls the evidence low quality.

TCS withdrawal was reported mostly on the face and genital area (99.3%) of women (81.0%) primarily in the setting of long-term inappropriate use of potent TCS. Burning and stinging were the most frequently reported symptoms (65.5%) with erythema being the most common sign (92.3%).

The authors of that withdrawal review were explicit that the evidence base is weak, which matters because the syndrome's existence is contested. (Source 13)

• Systematic review, Very low certainty.
• Size: 34 studies.
• Who: Patients using potent topical corticosteroids long term.
• How long: Not stated.
• Result: The review's own stated limitations were low quality of evidence, variable extent of data and lack of studies with rigorous methodology.
• Funding: Not stated in the recorded abstract.

Low quality of evidence, variability in the extent of data, and the lack of studies with rigorous steroid addiction methodology are limitations.

The FDA label records burning and stinging in 1% of treated patients in controlled trials, with itching, skin atrophy and cracking and fissuring of the skin less frequent, and Cushing's syndrome reported in infants and adults after prolonged use. (Source 14)

• Official position, Certainty not rated.
• Size: Not stated in this label section.
• Who: People treated with clobetasol propionate cream.
• How long: Controlled clinical trials, duration not stated in this section.
• Result: Burning and stinging in 1% of treated patients; skin atrophy, striae, hypopigmentation, perioral dermatitis, allergic contact dermatitis and secondary infection listed as further local reactions.
• Funding: Not applicable (regulatory label, Amneal Pharmaceuticals, published Sep 24 2026)

In controlled clinical trials, the most frequent adverse reactions reported for clobetasol propionate cream were burning and stinging sensation in 1% of treated patients. Less frequent adverse reactions were itching, skin atrophy, and cracking and fissuring of the skin.

The label states that clobetasol propionate cream suppressed the HPA axis at doses as low as 2 g a day for one week in people with eczema, which is why it sets a two-week limit and a 50 g per week ceiling. (Source 7)

• Official position, Certainty not rated.
• Size: Not stated in this label section.
• Who: Patients with eczema in the studies the label cites.
• How long: One week at 2 g/day.
• Result: HPA axis suppression at doses as low as 2 g/day for 1 week; the label directs that super-potent corticosteroids should not be used for more than 2 weeks at a time and only on small areas.
• Funding: Not applicable (regulatory label)

Clobetasol propionate cream produced HPA axis suppression when used at doses as low as 2 g/day for 1 week in patients with eczema.

A systematic review and meta-analysis of adrenal insufficiency after corticosteroid treatment of any kind concluded that no route, dose or duration can be assumed safe, with the pooled risk rising with higher dose and longer use. (Source 15)

• Meta-analysis, Moderate certainty.
• Size: 74 articles, 3,753 participants.
• Who: Adults treated with corticosteroids by any route for various conditions.
• How long: Varied; stratified analyses covered under 28 days to over 1 year.
• Result: Adrenal insufficiency in 4.2% after nasal administration (95% CI 0.5-28.9) up to 52.2% after intra-articular administration (95% CI 40.5-63.6); risk by dose 2.4% (low) to 21.5% (high)
• Funding: Independent academic meta-analysis.

there is no administration form, dosing, treatment duration, or underlying disease for which adrenal insufficiency can be excluded with certainty, although higher dose and longer use give the highest risk

What the evidence supports

A systematic review and network meta-analysis of topical psoriasis treatments found that strategies containing potent or very potent corticosteroids topped the efficacy ranking at both the trunk/limbs and the scalp, while coal tar and retinoids were no better than placebo. (Source 2)

• Systematic review, Moderate certainty.
• Size: 48 studies for trunk and limb psoriasis and 17 for scalp psoriasis, 22,028 patients in total.
• Who: Mostly people with at least moderate severity plaque psoriasis.
• How long: Continuous use up to 8 weeks and intermittent use up to 52 weeks.
• Result: Potent and very potent corticosteroid strategies dominated the treatment hierarchy at both body sites; response rates to very potent corticosteroids were 78% by investigator assessment and 39% by patient assessment.
• Funding: Research Support, Non-U.S. Gov't per the record; funding statement not in the abstract text recorded.

Strategies containing potent corticosteroids (alone or in combination with a vitamin D analogue) or very potent corticosteroids dominated the treatment hierarchy at both sites (trunk and limbs, scalp); coal tar and retinoids were no better than placebo.

A Cochrane review of topical treatments for genital lichen sclerosus, an off-label use, found clobetasol propionate 0.05% better than placebo on both participant-rated and investigator-rated outcomes. (Source 3)

• Meta-analysis, Low certainty.
• Size: 7 randomised controlled trials, 249 participants in total, covering 6 treatments.
• Who: Adults and children with genital lichen sclerosus.
• How long: Varied by trial; the review notes the included studies were mostly small.
• Result: Participant-rated improvement or remission of symptoms risk ratio 2.85 (95% CI 1.45 to 5.61); investigator-rated global degree of improvement standardised mean difference 5.74 (95% CI 4.26 to 7.23)
• Funding: Independent (Cochrane systematic review)

When compared to placebo in one trial, clobetasol propionate 0.05% was effective in treating genital lichen sclerosus in relation to the following outcomes: 'participant-rated improvement or remission of symptoms' (risk ratio (RR) 2.85, 95% confidence interval (CI) 1.45 to 5.61) and 'investigator-rated global degree of improvement' (standardised mean difference (SMD) 5.74, 95% CI 4.26 to 7.23).

A randomised placebo-controlled maintenance trial of clobetasol propionate 0.05% shampoo in scalp psoriasis reported that 31.1% of the clobetasol group were still relapse-free at six months versus 8.1% on vehicle, an absolute difference of 23 percentage points. (Source 16)

• Randomized trial, Moderate certainty.
• Size: 217 randomised into maintenance (106 clobetasol shampoo, 111 vehicle)
• Who: Adults with moderate to severe scalp psoriasis who responded to a 4-week induction course.
• How long: 4-week induction plus up to 6 months twice-weekly maintenance.
• Result: Relapse-free at 6 months 31.1% (33 of 106) with clobetasol propionate shampoo vs 8.1% (9 of 111) with vehicle; no greater incidence of skin atrophy, telangiectasia or HPA axis suppression than vehicle.
• Funding: Research Support, Non-U.S. Gov't per the record; the trial used a proprietary clobetasol shampoo formulation.

After 6 months 31.1% (33/106) of participants in the CP shampoo group were still relapse free versus 8.1% (9/111) of participants in the vehicle group.

What the evidence does not support

The same network meta-analysis found no significant difference between very potent corticosteroids such as clobetasol and ordinary potent corticosteroids, and found that investigators rated the response to very potent steroids roughly twice as highly as patients did. (Source 2)

• Systematic review, Moderate certainty.
• Size: 48 trunk/limb studies and 17 scalp studies, 22,028 patients.
• Who: Mostly people with at least moderate severity plaque psoriasis.
• How long: Up to 52 weeks.
• Result: No significant difference in achieving clear or nearly clear status between very potent corticosteroids and potent corticosteroids applied twice daily; investigator vs patient response rates to very potent corticosteroids 78% vs 39%.
• Funding: Research Support, Non-U.S. Gov't per the record.

No significant differences in achievement of clear or nearly clear status were observed between twice- and once-daily application of the same intervention or between any of the following: combined vitamin D analogue and potent corticosteroid (applied separately or in a single product), very potent corticosteroids, or potent corticosteroids (applied twice daily). Investigator and patient assessment of response differed significantly for some interventions (response rates to very potent corticosteroids: 78% and 39%, respectively).

A 2008 Cochrane review of 17 trials in alopecia areata, a condition clobetasol is used for off-label, found that none of the interventions tested beat placebo for hair growth; the steroids in those trials were topical and oral corticosteroids as a class and the review names no clobetasol trial. (Source 4)

• Meta-analysis, Very low certainty.
• Size: 17 trials, 540 participants, individual trials of 6 to 85 people.
• Who: People with alopecia areata, alopecia totalis or alopecia universalis.
• How long: Varied; the review notes most trials were small and poorly reported.
• Result: No significant treatment benefit in terms of hair growth versus placebo for any intervention, including topical and oral corticosteroids; no studies measured participant-assessed hair growth or quality of life.
• Funding: Independent (Cochrane systematic review)

Limit of this finding: This review tested topical and oral corticosteroids as a class. It does not name clobetasol propionate, and it found no randomised trials at all of intralesional corticosteroids. Read it as the absence of good evidence that topical steroids regrow hair in alopecia areata, not as a trial of clobetasol that came out negative. The search ran to 2006 and the review was published in 2008, so it says nothing about anything studied since.

Overall, none of the interventions showed significant treatment benefit in terms of hair growth when compared with placebo. We did not find any studies where the participants self-assessed their hair growth or quality of life.

The Cochrane genital lichen sclerosus review also found no difference between pimecrolimus and clobetasol in relieving itching or burning, so the advantage of the super-potent steroid was limited to the investigator-rated appearance. (Source 3)

• Meta-analysis, Low certainty.
• Size: One trial within a review of 7 RCTs and 249 participants.
• Who: People with genital lichen sclerosus.
• How long: Varied by trial.
• Result: Pruritus standardised mean difference -0.33 (95% CI -0.99 to 0.33) and burning/pain SMD 0.03 (95% CI -0.62 to 0.69) for pimecrolimus versus clobetasol, both non-significant; investigator-rated global improvement favoured clobetasol, SMD -1.64 (95% CI -2.40 to -0.87)
• Funding: Independent (Cochrane systematic review)

One trial found no differences between pimecrolimus and clobetasol propionate in relieving symptoms through change in pruritus (itching) (SMD -0.33, 95% CI -0.99 to 0.33) and burning/pain (SMD 0.03, 95% CI -0.62 to 0.69).

A 2014 review of sixteen clinical trials of topical corticosteroids reported that fifteen of them found no pathologic adrenal suppression, and that where measurable suppression did appear it often resolved on its own within weeks despite treatment continuing. (Source 17)

• Expert review, not systematic, Very low certainty.
• Size: Sixteen clinical trials reviewed from a PubMed literature search.
• Who: Patients treated with class I-IV topical corticosteroids, including clobetasol propionate.
• How long: Physiologic suppression seen from 1-2 weeks; the one trial with pathologic suppression ran up to 18 months.
• Result: 15 of 16 trials reported no pathologic adrenal suppression; in the single trial that did, patients used twice the maximum recommended amount of clobetasol propionate continuously for as long as 18 months; in about half of patients with physiologic suppression cortisol returned to normal within a few weeks despite continuous therapy.
• Funding: Not stated in the recorded abstract.

Limit of this finding: This is a review with no stated systematic method, so it is the authors' reading of sixteen trials rather than a pooled analysis, and the trials were not designed or sized to detect adrenal suppression. It sits directly against the same drug's FDA label, which states that clobetasol propionate cream suppressed the HPA axis at doses as low as 2 g/day for one week, and against a randomised study in this same entry in which 30.0% of patients on the marketed 0.05% cream had an abnormal ACTH stimulation test at 28 days. Read it as evidence that measurable suppression usually stays silent and recovers, not as evidence that suppression does not happen.

Fifteen of sixteen clinical trials reviewed did not report any pathologic adrenal suppression. In the single clinical trial that reported pathologic adrenal suppression, the patients used twice the maximum recommended amount of clobetasol propionate continuously for as long as 18 months.

Where the evidence is mixed

The same Cochrane review called its own evidence for clobetasol in genital lichen sclerosus limited, and listed what trials had still not measured: the best potency and regimen, how long remission lasts, and whether treatment lowers the risk of genital cancer. (Source 18)

• Systematic review, Low certainty.
• Size: 7 randomised trials in 249 participants across all topical interventions reviewed.
• Who: Adults and children with genital lichen sclerosus.
• How long: Trials were short; the review states duration of remission was not assessed.
• Result: Efficacy demonstrated for clobetasol propionate, mometasone furoate and pimecrolimus on limited evidence; optimal potency and regimen, duration of remission, prevention of flares, and reduction in risk of genital squamous cell carcinoma or intraepithelial neoplasia all listed as unanswered.
• Funding: Independent (Cochrane systematic review)

The current limited evidence demonstrates the efficacy of clobetasol propionate, mometasone furoate, and pimecrolimus in treating genital lichen sclerosus. Further RCTs are needed to determine the optimal potency and regimen of topical corticosteroids, examine other topical interventions, assess the duration of remission or prevention of flares, evaluate the reduction in the risk of genital squamous cell carcinoma or genital intraepithelial neoplasia

Where the research disagrees

How much the adrenal suppression caused by potent topical steroids actually matters clinically

• Broersen and colleagues, systematic review and meta-analysis of adrenal insufficiency after corticosteroid use (2015), meta-analysis of 74 studies and 3,753 participants across all routes of administration: the threshold to test corticosteroid users for adrenal insufficiency should be low in clinical practice, especially for those patients with nonspecific symptoms after cessation. (Source 15)
• Dhar and colleagues, review distinguishing physiologic from pathologic adrenal suppression with topical steroids (2014), narrative review of sixteen clinical trials, with no stated systematic method: Even when adrenal suppression occurs, topical corticosteroids are unlikely to be associated with clinical signs or symptoms of HPA axis suppression and are extremely safe as long as they are used within the current safety guidelines. (Source 19)

Whether topical corticosteroid withdrawal is a real entity distinct from the underlying skin disease flaring

• Hajar and colleagues, systematic review for the National Eczema Association (2015), systematic review of 34 mostly observational studies, which the authors rate as low quality evidence: TCS withdrawal is likely a distinct clinical adverse effect of TCS misuse. (Source 9)
• The same review's own stated limitations, which sceptics rely on, the review's self-assessment of its evidence base: Low quality of evidence, variability in the extent of data, and the lack of studies with rigorous steroid addiction methodology are limitations. (Source 13)

How much

• Reference intake: The amount and duration are set by the prescriber, not by the reader. As a position, the FDA label (Amneal clobetasol propionate cream 0.05%, SPL version 12, published Sep 24 2026) directs a thin layer applied to affected skin twice daily, with therapy discontinued once control is achieved. (Source 8)
• Upper limit: As a position, the same label sets a ceiling of two consecutive weeks of treatment and no more than 50 g per week, explicitly because of the potential to suppress the hypothalamic-pituitary-adrenal axis, and says use in children under 12 is not recommended. (Source 20)
• Studied: The phase 2a HPA-axis study applied clobetasol propionate 0.025% or the marketed 0.05% cream twice daily for 28 days in moderate-to-severe psoriasis. (Source 21)
• Studied: The scalp psoriasis maintenance trial used clobetasol propionate 0.05% shampoo once daily for up to four weeks, then twice weekly for up to six months. (Source 16)

A common belief, and what the research shows

The belief: A super-potent steroid like clobetasol clears skin disease better than an ordinary potent steroid, so it is the stronger and therefore better choice.

What the research shows: The largest synthesis of topical psoriasis trials did not find that. Across 22,028 patients it reported: No significant differences in achievement of clear or nearly clear status were observed between twice- and once-daily application of the same intervention or between any of the following: combined vitamin D analogue and potent corticosteroid (applied separately or in a single product), very potent corticosteroids, or potent corticosteroids (applied twice daily). It also noted that patients rated the response to very potent steroids far lower than investigators did.

Questions and answers

What is it?

Clobetasol propionate is a laboratory-made corticosteroid applied to the skin as a cream, ointment, gel, lotion, foam, shampoo or spray. It is classified as super-high potency, the strongest class of topical steroid. Its FDA label covers relief of the inflammatory and itchy features of corticosteroid-responsive skin diseases, with a stated two-week limit and a 50 g per week ceiling. (Source 20)

What does it do in the body?

It damps down inflammation, itching and blood-vessel dilation in the skin. The label states plainly that the mechanism of topical steroids in general is unclear, and offers only a postulated pathway through lipocortin proteins that block the release of arachidonic acid, the precursor of prostaglandins and leukotrienes. (Source 1)

Is it good or bad for you?

Both, and the dividing line is amount, site and duration. For short courses on plaque psoriasis it is among the most effective topical options in a 22,028-patient network meta-analysis, and in genital lichen sclerosus a Cochrane review found it clearly better than placebo. Used too long, over too much skin, on the face or under occlusion, it causes skin thinning and can suppress the adrenal stress response; 30% of patients in one 28-day psoriasis study had an abnormal ACTH test. For alopecia areata, Cochrane found no corticosteroid benefit over placebo at all. (Source 11)

How do you get more of it?

This question does not apply the way it would for a nutrient: clobetasol is prescription-only, is not present in food, and is not something to accumulate. The quantity is deliberately capped. For reference only, the label directs a thin layer twice daily with treatment limited to two consecutive weeks and no more than 50 g per week, and no occlusive dressings. (Source 8)

If it is harmful, what reduces it?

The drug is cleared by stopping it, and the label's own instruction when adrenal suppression is detected is to withdraw it, apply it less often, or swap to a weaker steroid; recovery of adrenal function is usually prompt. In the published Cushing's syndrome cases, recovery of the HPA axis took a mean of roughly three and a half months, so 'prompt' is not universal. (Source 7)

Why might someone be low in it or missing it?

Not applicable as a deficiency. The relevant question in reverse is why someone absorbs more of it than expected, and the label names the drivers: application to a large surface area, application under occlusion, and in children a higher ratio of skin surface area to body mass. Infants and children are therefore at greater risk of adrenal suppression and Cushing's syndrome than adults from the same amount. (Source 22)

Which whole foods contain it or feed it?

No food contains clobetasol and no dietary source exists; it is a synthetic molecule applied to skin. Nothing in the label we read describes a food or drink interaction. What the label does identify as changing how much enters the body is surface area, occlusion and duration of treatment. (Source 7)

What happens if you do not have it?

Not using clobetasol means the skin condition is managed some other way or not at all; there is no deficiency state. For psoriasis, the network meta-analysis found that ordinary potent steroids and vitamin D analogue combinations performed no worse than very potent ones, so the super-potent class is not the only effective choice. For alopecia areata there is no evidence of benefit to lose. (Source 23)

How can you test for it?

There is no blood level test for clobetasol itself. What is tested is its systemic effect on the adrenal axis, and the label names three: the ACTH stimulation test, a morning plasma cortisol, and a urinary free cortisol. These measure consequence rather than exposure, and a meta-analysis of 74 studies concluded the threshold for testing corticosteroid users should be low because no route or duration is reliably safe. (Source 7)

References

1. DailyMed / US FDA Structured Product Label. Clobetasol propionate cream, 0.05% - FDA prescribing information (Amneal Pharmaceuticals LLC, SPL version 12, published Sep 24, 2026) - CLINICAL PHARMACOLOGY. 2026. Read the source
2. The British journal of dermatology. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. [Abstract section of the abstract]. 2013. PMID 23413913, DOI 10.1111/bjd.12276. Read the source
3. The Cochrane database of systematic reviews. Topical interventions for genital lichen sclerosus. [Main results section of the abstract]. 2011. PMID 22161424, DOI 10.1002/14651858.cd008240.pub2. Read the source
4. The Cochrane database of systematic reviews. Interventions for alopecia areata. [Main results section of the abstract]. 2008. PMID 18425901, DOI 10.1002/14651858.cd004413.pub2. Read the source
5. The Journal of clinical endocrinology and metabolism. Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis. [Results section of the abstract]. 2015. PMID 25844620, DOI 10.1210/jc.2015-1218. Read the source
6. DailyMed / US FDA Structured Product Label. Clobetasol propionate cream, 0.05% - FDA prescribing information (Amneal Pharmaceuticals LLC, SPL version 12, published Sep 24, 2026) - PRECAUTIONS: General, irritation and concomitant skin infection paragraphs. 2026. Read the source
7. DailyMed / US FDA Structured Product Label. Clobetasol propionate cream, 0.05% - FDA prescribing information (Amneal Pharmaceuticals LLC, SPL version 12, published Sep 24, 2026) - PRECAUTIONS: General, systemic absorption and HPA axis paragraphs. 2026. Read the source
8. DailyMed / US FDA Structured Product Label. Clobetasol propionate cream, 0.05% - FDA prescribing information (Amneal Pharmaceuticals LLC, SPL version 12, published Sep 24, 2026) - DOSAGE AND ADMINISTRATION. 2026. Read the source
9. Journal of the American Academy of Dermatology. A systematic review of topical corticosteroid withdrawal ("steroid addiction") in patients with atopic dermatitis and other dermatoses. [Conclusions section of the abstract]. 2015. PMID 25592622, DOI 10.1016/j.jaad.2014.11.024. Read the source
10. Endocrine. Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature. [Abstract section of the abstract]. 2010. PMID 20972726, DOI 10.1007/s12020-010-9393-6. Read the source
11. Dermatology and therapy. Efficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm Study. [Results section of the abstract]. 2021. PMID 34453262, DOI 10.1007/s13555-021-00591-z. Read the source
12. Journal of the American Academy of Dermatology. A systematic review of topical corticosteroid withdrawal ("steroid addiction") in patients with atopic dermatitis and other dermatoses. [Results section of the abstract]. 2015. PMID 25592622, DOI 10.1016/j.jaad.2014.11.024. Read the source
13. Journal of the American Academy of Dermatology. A systematic review of topical corticosteroid withdrawal ("steroid addiction") in patients with atopic dermatitis and other dermatoses. [Limitations section of the abstract]. 2015. PMID 25592622, DOI 10.1016/j.jaad.2014.11.024. Read the source
14. DailyMed / US FDA Structured Product Label. Clobetasol propionate cream, 0.05% - FDA prescribing information (Amneal Pharmaceuticals LLC, SPL version 12, published Sep 24, 2026) - ADVERSE REACTIONS. 2026. Read the source
15. The Journal of clinical endocrinology and metabolism. Adrenal Insufficiency in Corticosteroids Use: Systematic Review and Meta-Analysis. [Conclusions section of the abstract]. 2015. PMID 25844620, DOI 10.1210/jc.2015-1218. Read the source
16. Cutis. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis. [Abstract section of the abstract]. 2010. PMID 20184211. Read the source
17. The Journal of dermatological treatment. Topical steroid risk analysis: differentiating between physiologic and pathologic adrenal suppression. [Results section of the abstract]. 2014. PMID 24171390, DOI 10.3109/09546634.2013.844314. Read the source
18. The Cochrane database of systematic reviews. Topical interventions for genital lichen sclerosus. [Authors' conclusions section of the abstract]. 2011. PMID 22161424, DOI 10.1002/14651858.cd008240.pub2. Read the source
19. The Journal of dermatological treatment. Topical steroid risk analysis: differentiating between physiologic and pathologic adrenal suppression. [Conclusion section of the abstract]. 2014. PMID 24171390, DOI 10.3109/09546634.2013.844314. Read the source
20. DailyMed / US FDA Structured Product Label. Clobetasol propionate cream, 0.05% - FDA prescribing information (Amneal Pharmaceuticals LLC, SPL version 12, published Sep 24, 2026) - INDICATIONS AND USAGE. 2026. Read the source
21. Dermatology and therapy. Efficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm Study. [Introduction section of the abstract]. 2021. PMID 34453262, DOI 10.1007/s13555-021-00591-z. Read the source
22. DailyMed / US FDA Structured Product Label. Clobetasol propionate cream, 0.05% - FDA prescribing information (Amneal Pharmaceuticals LLC, SPL version 12, published Sep 24, 2026) - PRECAUTIONS: Pediatric Use. 2026. Read the source
23. The Cochrane database of systematic reviews. Interventions for alopecia areata. [Authors' conclusions section of the abstract]. 2008. PMID 18425901, DOI 10.1002/14651858.cd004413.pub2. Read the source